Please ensure Javascript is enabled for purposes of website accessibility

Investing 101: Rallying Stocks Under $5 Undervalued to Analyst Estimates

By Kapit all – Updated Apr 6, 2017 at 8:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Do you think these stocks have more value to cash in?

Penny stocks have a solid reputation for being a risky investment. However, if the potential rewards excite you, then the list below may provide an interesting starting point for your search.

To create the following list of penny stocks (priced under $5) we chose the names with a market cap above $300M that also met the following bullish indicators:

  • Rallying above 20, 50, and 200 day market average (MA).
  • Undervalued to analyst target price by over 20%

Want clarification for the terms used above? You got it:

Analyst target prices can be very useful guides for investors. The target price is a price level set by analysts that, based on their data and estimates, represents their predictions for that company in the upcoming year. Because analysts often have different opinions, we use the average analyst target price.

When a company's current market price is deeply lagging to the target price, it may signal that the company has more value to price in (meaning, the stock price may rise).

When a stock is rallying, it means its price is performing above its market average price for a given time period. It is presented as a percentage of price relative to the average (i.e., 10% above the average). When a stock is performing above its 20 day moving average (MA), also known as simple moving average (SMA), as well as its 50 and 200 day moving averages, it signals bullish momentum.

Now that you're armed with information, how do you feel about the following list of stocks? Do you think they have more value to cash in? Will their momentum push them toward their target prices? Use the list below as a starting point for your own analysis. (Click here to access free, interactive tools to analyze these ideas.)

1. Abraxas Petroleum (Nasdaq: AXAS): Independent Oil & Gas Industry. Market cap of $410.03M. The stock is currently trading 14.55% above its SAM20, 11.79% above its SMA50, and 1.72% above its SMA200. Current price at $4.33 vs. target price at $6.20. Implies a potential upside of 43.33%. The stock is a short squeeze candidate, with a short float at 21.2% (equivalent to 8.32 days of average volume). The stock has had a good month, gaining 37.96%.

2. BioSante Pharmaceuticals (Nasdaq: BPAX): Biotechnology Industry. Market cap of $340.70M. The stock is currently trading 14.46% above its SAM20, 22.88% above its SMA50, and 68.38% above its SMA200. Current price at $3.45 vs. target price at $5.8. Implies a potential upside of 68.12%. The stock is a short squeeze candidate, with a short float at 14.9% (equivalent to 5.08 days of average volume). The stock has had a good month, gaining 40%.

3. Charming Shoppes (Nasdaq: CHRS): Apparel Stores Industry. Market cap of $512.66M. The stock is currently trading 2.91% above its SAM20, 4.63% above its SMA50, and 14.95% above its SMA200. Current price at $4.29 vs. target price at $6. Implies a potential upside of 39.86%. This is a risky stock that is significantly more volatile than the overall market (beta = 3.48). The stock is a short squeeze candidate, with a short float at 9.24% (equivalent to 8.53 days of average volume). The stock has had a good month, gaining 16.36%.

4. Curis (Nasdaq: CRIS): Biotechnology Industry. Market cap of $304.64M. The stock is currently trading 5.06% above its SAM20, 6.35% above its SMA50, and 37.26% above its SMA200. Current price at $3.81 vs. target price at $5.4. Implies a potential upside of 41.73%. The stock is a short squeeze candidate, with a short float at 7.47% (equivalent to 9.4 days of average volume). The stock has had a good month, gaining 30.82%.

5. Denny's (Nasdaq: DENN): Restaurants Industry. Market cap of $400.63M. The stock is currently trading 0.27% above its SAM20, -0.16% above its SMA50, and 3.44% above its SMA200. Current price at $3.95 vs. target price at $5. Implies a potential upside of 26.58%. The stock has gained 1% over the last year.

6. Dynavax Technologies (Nasdaq: DVAX): Drug Manufacturers Industry. Market cap of $353.52M. The stock is currently trading 5.83% above its SAM20, 11.08% above its SMA50, and 13.53% above its SMA200. Current price at $2.95 vs. target price at $6. Implies a potential upside of 103.39%. This is a risky stock that is significantly more volatile than the overall market (beta = 2.7). The stock is a short squeeze candidate, with a short float at 9.13% (equivalent to 9.68 days of average volume). The stock has had a good month, gaining 19.84%.

7. GenOn Energy (NYSE: GEN): Electric Utilities Industry. Market cap of $3.16B. The stock is currently trading 2.58% above its SAM20, 3.03% above its SMA50, and 3.53% above its SMA200. Current price at $3.97 vs. target price at $4.8889. Implies a potential upside of 23.15%. The stock has gained 11.41% over the last year.

8. Hyperdynamics (NYSE: HDY): Oil & Gas Drilling & Exploration Industry. Market cap of $700.90M. The stock is currently trading 1.46% above its SAM20, 4.61% above its SMA50, and 1.61% above its SMA200. Current price at $4.36 vs. target price at $8. Implies a potential upside of 83.49%. This is a risky stock that is significantly more volatile than the overall market (beta = 2.44). The stock is a short squeeze candidate, with a short float at 13.84% (equivalent to 6.66 days of average volume). The stock has gained 3.94% over the last year.

9. Immunomedics (Nasdaq: IMMU): Diagnostic Substances Industry. Market cap of $311.48M. The stock is currently trading 2.21% above its SAM20, 2.11% above its SMA50, and 11.43% above its SMA200. Current price at $4.08 vs. target price at $6.25. Implies a potential upside of 53.19%. The stock is a short squeeze candidate, with a short float at 13.96% (equivalent to 16.67 days of average volume). The stock has had a good month, gaining 14.4%.

10. Lexicon Pharmaceuticals (Nasdaq: LXRX):Biotechnology Industry. Market cap of $590.91M. The stock is currently trading 2.8% above its SAM20, 6.67% above its SMA50, and 2.02% above its SMA200. Current price at $1.72 vs. target price at $2.75. Implies a potential upside of 59.88%. The stock has had a good month, gaining 15.13%.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned above. Analyst ratings sourced from Zacks Investment Research.


Kapitall's Becca Lipman does not own any of the shares mentioned above. Target price information from Screener.co, all other data sourced from Finviz.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$10.24 (0.00%) $0.00
ANI Pharmaceuticals, Inc. Stock Quote
ANI Pharmaceuticals, Inc.
ANIP
$31.71 (-4.72%) $-1.57
Abraxas Petroleum Corporation Stock Quote
Abraxas Petroleum Corporation
AXAS
$0.99 (-9.17%) $0.10
Immunomedics, Inc. Stock Quote
Immunomedics, Inc.
IMMU
Denny's Corporation Stock Quote
Denny's Corporation
DENN
$9.57 (-2.25%) $0.22
Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
LXRX
$2.33 (-1.69%) $0.04
Curis, Inc. Stock Quote
Curis, Inc.
CRIS
$0.74 (-6.94%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.